Kenneth J. Woolcott is an American businessman, corporate attorney and entrepreneur with over 20 years of experience in the biotech and high tech industry. His early career in biotech included success at Hybritech (sold to Eli Lilly for over $400M) and over a decade as the General Counsel and Licensing Executive at IDEC Pharmaceuticals Corporation (now Biogen-IDEC), where he was part of the executive team that transformed a $50M Kliener Perkins start up into an $11B enterprise. IDEC’s success was based on developing and marketing Rituxan, one of the most successful cancer drugs in history that has profoundly enhanced the lives of millions of people throughout the world. (World-wide sales estimated at $10B annually.) From 2004 to 2010, Woolcott served as a trustee and chairman of the Tech Transfer Committee at the Sanford- Burnham Medical Research Institute. He continues to consult in the healthcare industry as Woolcott Bioscience Strategies. In 2002, he founded Six Degrees Capital a private investment firm, which included a minority interest in the former Seattle Supersonics of the NBA, numerous start up healthcare companies as well as the development of Kerry Park Court. His latest venture is iPi, the “iPioneering” space for consumer-driven curation that puts trust back into travel.